421 related articles for article (PubMed ID: 25815419)
1. Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
Arnow BA; Blasey C; Williams LM; Palmer DM; Rekshan W; Schatzberg AF; Etkin A; Kulkarni J; Luther JF; Rush AJ
Am J Psychiatry; 2015 Aug; 172(8):743-50. PubMed ID: 25815419
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.
Schatzberg AF; DeBattista C; Lazzeroni LC; Etkin A; Murphy GM; Williams LM
Am J Psychiatry; 2015 Aug; 172(8):751-9. PubMed ID: 25815420
[TBL] [Abstract][Full Text] [Related]
3. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment.
Saveanu R; Etkin A; Duchemin AM; Goldstein-Piekarski A; Gyurak A; Debattista C; Schatzberg AF; Sood S; Day CV; Palmer DM; Rekshan WR; Gordon E; Rush AJ; Williams LM
J Psychiatr Res; 2015 Feb; 61():1-12. PubMed ID: 25586212
[TBL] [Abstract][Full Text] [Related]
4. Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report.
Day CV; John Rush A; Harris AW; Boyce PM; Rekshan W; Etkin A; DeBattista C; Schatzberg AF; Arnow BA; Williams LM
J Affect Disord; 2015 Mar; 174():493-502. PubMed ID: 25554994
[TBL] [Abstract][Full Text] [Related]
5. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial.
Etkin A; Patenaude B; Song YJ; Usherwood T; Rekshan W; Schatzberg AF; Rush AJ; Williams LM
Neuropsychopharmacology; 2015 May; 40(6):1332-42. PubMed ID: 25547711
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
Bobo WV; Chen H; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Lesser IM; Kornstein SG; Wisniewski SR; Rush AJ; Shelton RC
J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
[TBL] [Abstract][Full Text] [Related]
7. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
Rush AJ; Wisniewski SR; Warden D; Luther JF; Davis LL; Fava M; Nierenberg AA; Trivedi MH
Arch Gen Psychiatry; 2008 Aug; 65(8):870-80. PubMed ID: 18678792
[TBL] [Abstract][Full Text] [Related]
8. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
[TBL] [Abstract][Full Text] [Related]
9. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
[TBL] [Abstract][Full Text] [Related]
10. Effects of antidepressant medication on emotion regulation in depressed patients: an iSPOT-D report.
McRae K; Rekshan W; Williams LM; Cooper N; Gross JJ
J Affect Disord; 2014 Apr; 159():127-32. PubMed ID: 24679400
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM
JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399
[TBL] [Abstract][Full Text] [Related]
12. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
Gaynes BN; Dusetzina SB; Ellis AR; Hansen RA; Farley JF; Miller WC; Stürmer T
J Clin Psychopharmacol; 2012 Feb; 32(1):114-9. PubMed ID: 22198447
[TBL] [Abstract][Full Text] [Related]
13. Heart rate variability as a biomarker of anxious depression response to antidepressant medication.
Kircanski K; Williams LM; Gotlib IH
Depress Anxiety; 2019 Jan; 36(1):63-71. PubMed ID: 30311742
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.
Shelton RC; Haman KL; Rapaport MH; Kiev A; Smith WT; Hirschfeld RM; Lydiard RB; Zajecka JM; Dunner DL
J Clin Psychiatry; 2006 Nov; 67(11):1674-81. PubMed ID: 17196045
[TBL] [Abstract][Full Text] [Related]
15. Dimensions of anxiety in Major depressive disorder and their use in predicting antidepressant treatment outcome: an iSPOT-D report.
Braund TA; Palmer DM; Williams LM; Harris AWF
Psychol Med; 2020 Apr; 50(6):1032-1042. PubMed ID: 31023398
[TBL] [Abstract][Full Text] [Related]
16. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
Trials; 2011 Jan; 12():4. PubMed ID: 21208417
[TBL] [Abstract][Full Text] [Related]
17. Clinically Useful Genetic Markers of Antidepressant Response: How Do We Get There From Here?
McMahon FJ
Am J Psychiatry; 2015 Aug; 172(8):697-9. PubMed ID: 26234589
[No Abstract] [Full Text] [Related]
18. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.
McGrath PJ; Stewart JW; Fava M; Trivedi MH; Wisniewski SR; Nierenberg AA; Thase ME; Davis L; Biggs MM; Shores-Wilson K; Luther JF; Niederehe G; Warden D; Rush AJ
Am J Psychiatry; 2006 Sep; 163(9):1531-41; quiz 1666. PubMed ID: 16946177
[TBL] [Abstract][Full Text] [Related]
19. Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study.
Shilyansky C; Williams LM; Gyurak A; Harris A; Usherwood T; Etkin A
Lancet Psychiatry; 2016 May; 3(5):425-35. PubMed ID: 26995298
[TBL] [Abstract][Full Text] [Related]
20. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
Leelahanaj T
J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
